Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
533-45-9
Molecular formula
C6H8ClNS
Molecular weight
161.65 g/mol
Drug class
Thiazole sedative-hypnoticpositive allosteric modulator of GABAA receptors
Mechanism of action
Enhances GABA-mediated inhibitory neurotransmission through actions at GABAA receptor complexes and may also affect glycine-mediated inhibition. It produces sedative, hypnotic and anticonvulsant effects.
Indications / reported uses
Short-term treatment of severe agitation and alcohol withdrawal symptoms in selected hospital settings in countries where clomethiazole is authorised
Historically used for short-term insomnia in selected patients; it carries respiratory-depression and dependence risks and is not a routine long-term hypnotic
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Clomethiazole PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Clomethiazole Permitted Daily Exposure (PDE) report (the Clomethiazole PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Clomethiazole Occupational Exposure Limit (OEL) report (the Clomethiazole OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.